Download MendeleyAnalogues of the pan-selectin antagonist rivipansel (GMI-1070).
Wagner, B., Smiesko, M., Jakob, R.P., Muhlethaler, T., Cramer, J., Maier, T., Rabbani, S., Schwardt, O., Ernst, B.(2024) Eur J Med Chem 272: 116455-116455
- PubMed: 38728868
- DOI: https://doi.org/10.1016/j.ejmech.2024.116455
- Primary Citation of Related Structures:
8R5L, 8R5M - PubMed Abstract:
The selectin family consisting of E-, P- and L-selectin plays dominant roles in atherosclerosis, ischemia-reperfusion injury, inflammatory diseases, and metastatic spreading of some cancers. An early goal in selectin-targeted drug discovery campaigns was to identify ligands binding to all three selectins, so-called pan-selectin antagonists. The physiological epitope, tetrasaccharide sialyl Lewis x (sLe x , 1) binds to all selectins, albeit with very different affinities. Whereas P- and L-selectin require additional interactions contributed by sulfate groups for high binding affinity, E-selectin can functionally bind sLe x -modified glycolipids and glycoproteins. Rivipansel (3) marked the first pan-selectin antagonist, which simultaneously interacted with both the sLe x and the sulfate binding site. The aim of this contribution was to improve the pan-selectin affinity of rivipansel (3) by leveraging a new class of sLe x mimetics in combination with an optimized linker length to the sulfate bearing group. As a result, the pan-selectin antagonist 11b exhibits an approximatively 5-fold improved affinity for E-, as well as P-selectin.
Organizational Affiliation:
University of Basel, Department of Pharmaceutical Sciences, Group Molecular Pharmacy, Klingelbergstrasse 50, 4056, Basel, Switzerland.
